Benjamin Greenberg, MD

In this episode focused on first-line MS treatments, Dr. Williams poses the practical question: when a newly diagnosed, treatment-naive patient with relapsing-remitting MS sits across from you, what guides your treatment recommendation?

How MS therapy choices balance patient preference, payer coverage, dosing convenience, and family planning as high-efficacy options expand.

In this episode, panelists explore the question of "MS Treatment Strategy: High-Efficacy Therapy vs. Escalation Approach." Dr. Williams frames the central question: with earlier MS diagnoses now possible, how has treatment philosophy shifted? The traditional "start low, go slow" escalation model has given way to a high-efficacy-first approach for many clinicians.

Welcome back to another Neurology Live Peer Exchange series. In this episode titled "Evolving MS Diagnostic Criteria: 2024 McDonald Criteria and What's New," moderator Dr. Mitzi Joi Williams discusses multiple sclerosis with Dr. Stephen Krieger.

Experts discuss the optimistic future of MS treatment, emphasizing early diagnosis, consistent care, and a partnership approach for improved patient outcomes.

Healthcare professionals discuss setting realistic long-term goals for MS patients, emphasizing the importance of early treatment and patient education.

Healthcare professionals emphasize the importance of partnership in MS treatment, focusing on personalized goals and empowering patients to take control of their health.

Experts share effective communication strategies and metaphors to enhance patient understanding and engagement in managing neurological disorders.

Effective patient communication transforms complex disease concepts into understandable insights, fostering trust and empowering individuals with MS.

Experts discuss the importance of systematic longitudinal follow-up in multiple sclerosis care, emphasizing holistic assessments and cognitive testing for better patient outcomes.

Benjamin Greenberg, MD, internationally recognized NMOSD expert, discussed the growing use of recently approved therapies, the importance of early diagnosis, and investigational approaches, including biomarker development and CAR-T therapy, for NMOSD Awareness Month.

Experts discuss reconciling discrepancies in MS diagnosis through clinical judgment, imaging, and biomarker analysis for better patient outcomes.

Discover emerging imaging techniques and biomarkers for multiple sclerosis that enhance clinical practice and improve patient outcomes.

Experts discuss current imaging techniques and biomarkers for monitoring disease progression in MS, emphasizing the need for improved metrics and awareness.

Healthcare professionals explore how subtle MS progression impacts daily life and quality of life, emphasizing the importance of targeted assessments.

Clinicians discuss distinguishing between true progression and pseudo-relapses in MS, emphasizing patient insights and monitoring changes over time.

Experts discuss identifying early signs of disease progression through patient history, symptoms, and innovative monitoring techniques for better care.

Experts discuss the impact of genetic, lifestyle, and environmental factors on multiple sclerosis progression and disability management.

Explore the complexities of disease biology, focusing on relapsing and progressive mechanisms that impact treatment and patient outcomes.

Benjamin Greenberg, MD, MHS, a nationally recognized neuroimmunologist, spoke about the clinical impact of the latest NMOSD recommendations and their implications for diagnosis and care.

Experts discuss the complexities of MS progression, exploring traditional phenotypes and the evolving understanding of the disease as a continuum.

Experts discuss the complexities of MS progression, exploring traditional phenotypes and the evolving understanding of the disease as a continuum.

In this episode, a pair of neuroimmune experts discussed some of the emerging research for patients with MOGAD, highlighting the need for immunological markers, remodeling therapies, and enhancements to diagnostic criteria. [WATCH TIME: 5 minutes]

The pair of neurologists provided clinical insight on a number of lingering non-treatment unmet needs for patients with MOGAD, including improved care for pediatric patients and underreported complications like sleep disturbances and genitourinary issues in adults. [WATCH TIME: 5 minutes]

In this discussion, the pair of neurologists explore the latest drug development and ongoing clinical trials for MOGAD, a rare neuroimmune disorder. [WATCH TIME: 4 minutes]

In this segment, Bennett and Greenberg explore the diagnosis, acute treatment, and long-term management of MOGAD, highlighting current therapies and ongoing research. [WATCH TIME: 8 minutes]

In this episode, Greenberg and Bennett provide some perspective on the fluidity of MOGAD diagnosis and how it could potentially change over time as more is understood about neuroimmune disorders. [WATCH TIME: 5 minutes]

In this segment, the duo of neurologists provided a number of informative considerations treating clinicians should take when diagnosing MOGAD, emphasizing careful testing and interpretation of data in this complex process. [WATCH TIME: 4 minutes]

A panel of neurology experts detailed the importance that community leadership and creating a positive environment can do for patients with rare neurologic disorders [WATCH TIME: 5 minutes]

Sanford Siegel, Douglas Kerr, MD; and Benjamin Greenberg, MD, detailed the need for greater research on treatment strategies that repair myelin improve neurodegeneration, as well as expanded knowledge on how neuroimmune disorders present. [WATCH TIME: 5 minutes]